RESEARCH CENTER

CONTACT US

To learn more about how to be involved

in the clinical trials listed below

RESEARCH CENTER TEAM​

 

From right to left:

Principal Investigator, Shekhar Challa, MD

Clinical Research Staff, Susie Roeder

Sub-Investigator, Laura Welborn, APRN-C

Sub-Investigator, Balaji Datti, MD

 

PREMIER GI RESEARCH CENTER IN KANSAS

For more information regarding all KMC clinical trials, please contact Susie Roeder at 785-295-0938. Call today!

KMC Research Center

2200 SW 6th Ave.

Topeka, KS 66606

 

KMC CURRENT CLINICAL TRIALS:

1. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH).

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with Stage 2 or 3 NASH, ages 18-75

Duration: Minimum 1 Year

Compensation: Yes

 

2. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Adult Subjects with Compensated Cirrhosis Due to Nonalcholic Steatohepatitis (NASH).

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with NASH, ages 18 and older

Duration: Minimum 18 Months

Compensation: Yes

 

3. A Phase 3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Prevention of Recurrent Clostridium Difficile Infection (CD3-2).

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with recurrent C Diff, ages 18 and older

Duration: Minimum 6 Months

Compensation: Yes

 

 

4. A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis.

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with UC, ages 18-80

Duration: 54 Week Treatment

Compensation: Yes

 

5. A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Operationally Seamless 2b/3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease.

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with Moderately to Severely Active Crohn’s Disease, ages 16-80

Duration: 52 Week Treatment

Compensation: Yes

 

6. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease (GERD) While Receiving PPI.

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with GERD, ages 18 and older

Duration: Minimum 8 Weeks

Compensation: Yes

 

7. A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Steatohepatitis (NASH) stages 1,2,3 to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation.

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with Stages 1,2,3 NASH, ages 18 and older

Duration: Up to 54 Months

Compensation: Yes

 

8. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relamorelin in Patients with Diabetic Gastroparesis.

*There are three separate arms of this study: short term, long term, and one arm for patients that have fewer episodes of vomiting.

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with Diabetic Gastroparesis, ages 18 and older

Duration: 52 Week Treatment

Compensation: Yes

 

9. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Larazotide for the Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten-Free Diet (GFD).

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with Celiac Disease on GFD, ages 18 and older

Duration: Minimum 12 Weeks

Compensation: Yes

 

10. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD1).

 

Type of Study: Investigational medicine (Chance of placebo)

Who: Individuals with NAFLD, ages 18 and older

Duration: 52 Week Treatment

Compensation: Yes

 

Upcoming Trials: A Phase 3 Idiopathetic Gastroparesis Study Coming in 2020!

 

For a complete list of trials KMC is participating in, click here.

Interested in participating in or learning more about a clinical trial? Please call Susie Roeder at 785-295-0938. 

LOCATIONS

CONTACT

Kansas City, Independence, Olathe, Shawnee, Leawood, Topeka, Lawrence, Emporia, Manhattan

DERMATOLOGY phone numbers and addresses

MEDSPA phone numbers and addresses 

GASTROENTEROLOGY phone number and address

KMC CAREERS

  • White Facebook Icon
  • YouTube - White Circle

© 2020 Kansas Medical Clinic, PA ​ - If you have a medical emergency, please call 911.  All information provided herein is for educational purposes only. If you have a medical condition, please consult a physician to get a proper diagnosis and treatment plan.